Northway Biotech
16.11.2023 14:21:41 CET | ACCESS Newswire | Press release
VILNIUS, LITHUANIA / ACCESSWIRE / November 16, 2023 / Northway Group is embarking on a project to establish Europe's largest biotechnology hub, BIO CITY, in Vilnius, the capital of Lithuania. It includes 6 large biotechnological complexes - 4 state-of-the-art GMP manufacturing plants and 2 advanced scientific research centres - that will be built in an area equivalent to 10 football fields. The total investment for this biotech campus is projected to reach approximately 7 billion euros over the next decade.
Northway Group is in the process of constructing Europe's largest biotechnology hub, with the inaugural Gene Therapy Center set to be operational in 2024.
"A science-based economy, supported by bright minds and intelligent entrepreneurs, is the foundation for Lithuania's long-term economic prosperity. In the past, our growth was constrained by a lack of fossil resources, but today, we are boldly moving forward, relying on modern technologies. The new biotechnology hub embodies the direction of Lithuania's innovative economy. It also promises new inventions that will enable people with serious illnesses to become full members of society, thereby reducing exclusion," says the President of the Republic of Lithuania, Gitanas Nausėda.
Prof. Vladas Algirdas Bumelis, founder and CEO of Northway Biotech and Celltechna, key components of the Northway Group, highlighted Lithuania's strong global standing in biotechnology. The aim of the BIO CITY project is to further solidify this position with four advanced biomanufacturing facilities and two innovative research centres, significantly boosting Lithuania's prominence in the international biotech sphere.
The Speaker of the Seimas, parliament of Lithuania, states that the new biotech city being developed in Vilnius will strengthen the competitiveness of our country. "Lithuanian life sciences industry has ambitions and potential to become a global leader in this field: a leader who will significantly contribute to the development of scientific research for the well-being of man, nature and planet, and will facilitate new opportunities to deal with global health, sustainable development and other challenges," says Viktorija Čmilytė-Nielsen.
Vision of BIO CITY: A European Biotechnology Leader
"We envision BIO CITY as a frontrunner in the European biotechnology, by uniquely integrating various biotech segments into a single, synergistic ecosystem. This multifunctional complex will catalyse interdisciplinary collaborations, the quick realisation of ideas and technological advancements. Our unique model, which brings together diverse biotechnology fields in one location, is set to revolutionise the European biotech landscape," said Prof. V. A. Bumelis.
Gene Therapy Centre will Open in 2024
The first facility to open its doors in the biotech hub BIO CITY will be the Gene Therapy Centre, which is currently under construction and is being built by Northway Group's subsidiary, Celltechna. This centre, the first and so far the only one of its kind in the Baltic States, will bolster Lithuania's role in gene therapy, addressing the needs of the 280 million individuals worldwide who are affected by genetic diseases.
"Our state-of-the-art facility will be instrumental in both research and production, offering new treatments for previously incurable diseases. This will not only augment our CDMO (Contract Development and Manufacturing Organisation) capabilities, but also position us for global competition and collaborations," added Prof. V. A. Bumelis.
The Gene Therapy Centre, which is expected to become operational in the second quarter of 2024, will specialise in gene therapy research and GMP manufacturing. Representing an investment of 50 million euros, the facility will span 8,000 square metres and is anticipated to create over 100 high-value jobs. The centre will work in synergy with Northway Biotech. Established in 2004, Northway Biotech is a leading provider of CDMO services in the field of biologics, with a focus on the development and manufacturing of recombinant proteins and antibodies.
A Comprehensive Lithuanian Biotech Hub
By 2030, BIO CITY will see the inauguration of five additional complexes, including centres for R&D and Virology, Life Sciences Industry Smart Services, Stem Cell Research and 3D Bioprinting, as well as two large-scale production centres for mammalian and microbial products. The entire BIO CITY complex will span an area equivalent to 10 football fields, with the total investment expected to reach around 7 billion euros over the next decade.
"We will not only focus on contract development and manufacturing services, but will also invest significantly in the operation of scientific research centres. Scientific activity enhances a country's competitiveness and generates value in various forms, beyond just the economic aspect. Modern biotechnologies, such as gene editing and cell therapies, are advancing rapidly. Lithuania can pride itself on having some of the most talented scientists and robust expertise in these areas. The development of the biotech campus in Vilnius means we are poised to foster new partnerships with innovative startups, research institutions and pharmaceutical companies on a global scale. We are actively seeking partnerships and offer a warm invitation to investors who are enthusiastic about joining this exciting venture," said Prof. V. A. Bumelis.
Upon its completion, BIO CITY is expected to offer employment to approximately 2,100 highly skilled professionals, including scientists, biotechnologists, and medical engineers.
Lithuania is Among the Leaders in the Global Biotechnology Market
The global biotechnology market, currently valued at over 1,130 billion euros, is anticipated to grow to be worth more than 2,775 billion euros by 2030. Lithuania holds a strong position in this market, ranking among the Top 35 innovative countries in the biotechnology field, according to Scientific American Worldview.
"Every year, Lithuania is mentioned in the field of Life Sciences more often, and the ambitious BIO CITY project will contribute to our leadership. Our vision is coming to life - we are talking about world-class Life Sciences infrastructure and a competitive sector capable of building innovative products. In 2022, companies in the sector posted combined revenues of 1.5 billion euros, while exporting their goods to more than 100 countries. Overall, Life Sciences is a leading sector in Lithuania, when it comes to creating and implementing innovative solutions," states Aušrinė Armonaitė, the Minister of the Economy and Innovation.
Over 80 life science companies operate in Lithuania, contributing about 2.5% to the country's GDP. The Northway group, a key player in Lithuania's biotech sector, manages seven companies: five in Lithuania and one each in the UK and the US, with the US entity being recognised as the largest biotech investor from the Baltic region in recent years. Employing more than 200 specialists, these companies provide services to a diverse array of international biopharmaceutical firms, ranging from small to large enterprises, predominantly operating in both Europe and the US.
BIO CITY Contacts:
Vladas Algirdas Bumelis
CEO and Chairman of the Board
vladas.bumelis@northwaybiotech.com
Contact Information:
Vladas Bumelis
CEO and Chairman of the Board
vladas.bumelis@northwaybiotech.com
Related Files
BIO CITY LOGO_ORANGE.png
BIO CITY LOGO_BLACK.png
Related Images
SOURCE: Northway Healthcare Group
To view this piece of content from www.accesswire.com, please give your consent at the top of this page.View source version on accesswire.com:
https://www.accesswire.com/804258/the-largest-biotech-city-in-europe-will-soon-be-built-with-an-investment-amounting-to-7-billion-euros
To view this piece of content from www.accesswire.com, please give your consent at the top of this page.
About ACCESS Newswire
Subscribe to releases from ACCESS Newswire
Subscribe to all the latest releases from ACCESS Newswire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from ACCESS Newswire
Steelcase Names Proven Growth Leader Irene Tasi as President9.9.2026 21:00:00 CEST | Press release
Experienced commercial and innovative leader will guide the Steelcase business as the company builds on its design leadership, dealer network and customer-focused strategy. GRAND RAPIDS, MI / ACCESS Newswire / September 9, 2026 / Steelcase today announced Irene Tasi has been named president of Steelcase and will lead the business effective September 14, 2026. Tasi brings more than 25 years of executive leadership experience with a track record leading complex businesses through growth, portfolio development, commercial execution, and organizational change. Her background includes full P&L responsibility, enterprise strategy, innovation, and sales and channel leadership. She will report to Jeff Lorenger, Chairman, President and Chief Executive Officer, HNI Corporation. "Irene brings a combination of commercial leadership, product innovation, operating discipline, and customer focus that makes her exceptionally well-suited to lead Steelcase," said Lorenger. "She has led businesses where
Global Study: Nursing Shortages Require Workforce Policy Solutions, Not Recruitment Campaigns Alone9.9.2026 15:01:00 CEST | Press release
Why people choose nursing, and why they leave, comes down to the same factors PHILADELPHIA, PA / ACCESS Newswire / September 9, 2026 / The global nursing shortage cannot be solved simply by encouraging more people to enter the profession, according to a new evidence brief from the Global Nursing Workforce Centre (GNWC), a joint initiative of the International Council of Nurses (ICN) and TruMerit®. Drawing on research from 42 countries, the brief, The Attractiveness of Nursing for Prospective and Current Nursing Students, finds that the factors influencing people to choose nursing are often the same ones that determine whether they stay. Working conditions, compensation, professional respect, career development opportunities, workplace experiences, and the ability to provide quality care all shape nursing attractiveness to current nurses as well as potential recruits. The findings suggest that countries seeking to strengthen their nursing workforce must focus not only on recruitment, bu
Leggett Dynamics Showcases Award-Finalist Innovations at Automotive News Congress in Detroit9.9.2026 13:00:00 CEST | Press release
Mid-Class Massage System & Smart Brushless Motor Named Finalist For 2026 Automotive News PACE & PACE Pilot Awards DETROIT, MI / ACCESS Newswire / September 9, 2026 / Leggett Dynamics will showcase two next-generation comfort and motion technologies at the 50th Automotive News Congress, September 29-30 in Detroit, Michigan. Both innovations have been named finalists for 2026 Automotive News awards, recognizing the company's commitment to developing innovative comfort and motion solutions that address the evolving needs of automakers and consumers. Leggett Dynamics' Mid-Class Massage System has been named a finalist for the 2026 Automotive News PACE Award, while the company's Smart Brushless Motor has been named a finalist for the 2026 Automotive News PACE Pilot Award. During the 50th Automotive News Congress event, attendees are invited to visit Leggett Dynamics' showcase to explore both technologies firsthand and connect with the team behind their development. The showcase will offer a
IXOPAY Launches Agentic Suite to Help Merchants Support Agentic Commerce and Automate Payment Workflows9.9.2026 12:00:00 CEST | Press release
Flexible, Protocol-Agnostic Suite Helps Merchants Support Agentic Commerce, Preserve Transaction Context and Accelerate Payment Workflows With Secure AI Access DALLAS, TX / ACCESS Newswire / September 9, 2026 / IXOPAY, a leader in payment infrastructure enabling fluid commerce, today announced the launch of the IXOPAY Agentic Suite, a flexible set of tools designed to help merchants prepare for both new agentic buying experiences and the growing role of AI in payment operations. The suite includes Payment Agent, which provides protocol-agnostic connectivity between agentic shopping experiences and existing payment infrastructure; Universal Tokens to preserve transaction context so merchants can confidently participate in agentic commerce while reducing risk; and Model Context Protocol (MCP) Server, which gives approved AI assistants secure and governed access to payment and tokenization capabilities. Together, the suite gives merchants a faster and more flexible way to launch new buyin
Learnis: A New International Network for Transformative Education is Born.8.9.2026 23:05:00 CEST | Press release
Three groups of companies from Italy, Spain and the United States unite in a new corporate network structure, strong of a 20-year shared method that converges under one masterbrand - Learnis, Your transformative education. MILAN, IT / ACCESS Newswire / September 8, 2026 / A new corporate structure brings together Genio Net, the Italian business network directed by Massimo De Donno; Crecimiento Personal SL, the company headed by Giacomo Navone as the franchisor of the Spanish network; and Genius in 21 Days LLC, founded in the United States by Stephanie Turconi and Cosimo Intermite. Across the three countries, the group runs more than 50 learning centers, working with certified instructors and tutors, and reaching over 5,000 participants each year with its immersive courses, training paths and publications, with a focus on personalized study methods and learning. The group has chosen to introduce itself publicly on September 8, 2026, the International Literacy Day. Promoted by UNESCO to
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom